Dr. Reddy's Laboratories Company Profile (NYSE:RDY)

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited is an integrated global pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Global Generics segment consists of its business of manufacturing and marketing prescription and over-the-counter (OTC) finished pharmaceutical products, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients (API) and intermediates. Proprietary Products segment consists of its differentiated formulations business, its new chemical entities (NCEs) business and its dermatology focused specialty business. The Company's OTC brands include Doan's, Bufferin, Nupercainal Ointment, Cruex Nail Gel, Comtrex and Myoflex.

Industry, Sector and Symbol:

Sector: Medical
Industry: Drug Manufacturers - Other
Sub-Industry: N/A
Exchange: NYSE
Symbol: RDY
CUSIP:

Key Metrics:

Previous Close: $47.83
50 Day Moving Average: $46.17
200 Day Moving Average: $46.70
52-Week Range: $40.67 - $68.00
Trailing P/E Ratio: 36.43
Foreward P/E Ratio: 21.55
P/E Growth: 1.69
Market Cap: $7.92B
Outstanding Shares: 165,530,000
Beta: 0.83

Profitability:

Net Margins: 10.09%
Return on Equity: 12.27%
Return on Assets: 7.43%

Debt:

Debt-to-Equity Ratio: 0.10%
Current Ratio: 1.52%
Quick Ratio: 1.10%

Additional Links:

Companies Related to Dr. Reddy's Laboratories:

Consensus Ratings for Dr. Reddy's Laboratories (NYSE:RDY) (?)

Ratings Breakdown:	4 Sell Ratings, 3 Hold Ratings, 1 Buy Rating
Consensus Rating:	Hold (Score: 1.63)
Consensus Price Target:	$41.90 (12.40% downside)

Analysts' Ratings History for Dr. Reddy's Laboratories (NYSE:RDY)

Show:

Date	Firm	Action	Rating	Price Target
7/27/2016	HSBC	Downgrade	Hold -> Reduce
7/27/2016	Jefferies Group	Downgrade	Hold -> Underperform	$45.00 -> $41.90
7/26/2016	Credit Suisse Group AG	Downgrade	Neutral -> Underperform
5/2/2016	Goldman Sachs Group Inc.	Initiated Coverage	Neutral
2/10/2016	Credit Agricole SA	Upgrade	Underperform -> Buy
12/2/2015	Deutsche Bank AG	Initiated Coverage	Sell
11/10/2015	Citigroup Inc.	Downgrade	Buy -> Neutral
11/6/2015	Barclays PLC	Downgrade	Overweight -> Equal Weight

(Data available from 9/27/2014 forward)

Earnings History for Dr. Reddy's Laboratories (NYSE:RDY)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/26/2016	Q117		$0.00	$557.00 million	$479.00 million	View	Listen
5/12/2016	Q416		$0.07	$2.41 billion	$567.00 billion	View	Listen
2/9/2016	Q316		$0.51	$2.48 million	$599.00 million	View	N/A
10/29/2015	Q116		$0.65	$2.54 billion		View	Listen
5/12/2015	Q415		$0.49	$559.00 million	$621.00 million	View	Listen
1/29/2015	Q315		$0.53	$561.00 million	$610.00 million	View	N/A
7/30/2014	Q115		$0.54	$474.00 million	$486.00 million	View	N/A
5/13/2014	Q414	$0.52	$0.47	$557.00 million	$580.00 million	View	N/A
2/11/2014	Q314	$0.45	$0.59	$558.20 million	$571.00 million	View	N/A
10/31/2013	Q214	$0.46	$0.65	$561.00 million	$537.00 million	View	N/A
7/30/2013	Q413	$0.43	$0.40	$551.40 million	$478.00 million	View	N/A
5/14/2013			$0.60			View	N/A
2/14/2013	Q313		$0.40	$505.00 million	$522.00 million	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Dr. Reddy's Laboratories (NYSE:RDY)

Current Year EPS Consensus Estimate: $1.33 EPS
Next Year EPS Consensus Estimate: $2.22 EPS

Current Dividend Information for Dr. Reddy's Laboratories (NYSE:RDY)

Annual Dividend:	$0.28
Dividend Yield:	0.59%
Dividend Growth:	8.80% (3 Year Average)
Payout Ratio:	21.05% (Based on Trailing 12 Months of Earnings) 21.05% (Based on Current Year Consensus EPS Estimate) 12.61% (Based on Next Year Consensus EPS Estimate)
Track Record:	2 Years of Consecutive Dividend Growth

Dividend History for Dr. Reddy's Laboratories (NYSE:RDY)

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/6/2016	Annual	$0.28		7/14/2016	7/18/2016	7/18/2016

(Data available from 1/1/2013 forward)

Insider Trading History for Dr. Reddy's Laboratories (NYSE:RDY)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Dr. Reddy's Laboratories (NYSE:RDY)

Date	Headline
	Can Shares Of Dr. Reddy's Laboratories Ltd (NYSE:RDY) Hit $56? - Investor Newswire (NYSE:RDY) www.investornewswire.com - September 27 at 6:52 PM
	Buy Dr. Reddy's Laboratories, target Rs 3310: Siddarth Bhamre (NYSE:RDY) economictimes.indiatimes.com - September 27 at 11:39 AM
	ETF’s with exposure to Dr. Reddy’s Laboratories Ltd. : September 26, 2016 (NYSE:RDY) www.capitalcube.com - September 26 at 11:51 AM
	Dr Reddys Laboratories Ltd allots 13188 Equity Shares on exercise of ESOP (NYSE:RDY) www.equitybulls.com - September 24 at 11:24 AM
	Analyst Views and Growth Review for Dr. Reddy's Laboratories Ltd. (NYSE:RDY) - Post News (NYSE:RDY) www.kentuckypostnews.com - September 23 at 11:43 AM
	Active Watch List: Harley-Davidson (NYSE:HOG), Symantec Corporation (NASDAQ:SYMC), Dr. Reddy's Laboratories ... - KC Register (NYSE:RDY) www.kcregister.com - September 22 at 11:48 AM
	Dr. Reddy's Laboratories Launches Generic Version of Zemplar in U.S. (NYSE:RDY) - Post News (NYSE:RDY) www.kentuckypostnews.com - September 21 at 6:35 PM
	Dr Reddy’s Laboratories launches Paricalcitol injection in the US Market (NYSE:RDY) rtn.asia - September 21 at 11:03 AM
	Shares Of Dr. Reddy's Laboratories Ltd (NYSE:RDY) Expected To Hit $56 - Investor Newswire (NYSE:RDY) www.investornewswire.com - September 19 at 6:57 PM
	Dr. Reddy's Laboratories Announces the Launch of Paricalcitol ... - Business Wire (press release) (NYSE:RDY) www.businesswire.com - September 19 at 6:57 PM
	Dr. Reddy's Laboratories Announces the Launch of Paricalcitol Injection in the U.S. Market - Yahoo Sports (NYSE:RDY) sports.yahoo.com - September 19 at 11:33 AM
	Vigorous Stocks Need to Consider: General Electric (NYSE:GE), Dr ... - Street Wise Report (press release) (blog) (NYSE:RDY) streetwisereport.com - September 19 at 11:33 AM
	Dr. Reddy's Laboratories announces the launch of Paricalcitol Injection in the U.S. Market (NYSE:RDY) www.publicnow.com - September 19 at 11:33 AM
	Dr. Reddys Labs (RDY), Amgen (AMGN) Enter Expanded Collaboration in India - StreetInsider.com (NYSE:RDY) www.streetinsider.com - September 18 at 11:12 AM
	Dr Reddy’s to commercialise 3 drugs of Amgen in Indian market (NYSE:RDY) www.thehindubusinessline.com - September 16 at 6:46 PM
	Dr. Reddy's to distribute three new Amgen products in India (NYSE:RDY) seekingalpha.com - September 16 at 10:34 AM
	Dr. Reddy's Expands Collaboration To Market Amgen's 3 Medicines In India (NYSE:RDY) www.rttnews.com - September 16 at 10:34 AM
	Dr. Reddy’s Expands Strategic Collaboration with Amgen in India (NYSE:RDY) www.publicnow.com - September 16 at 10:34 AM
	Dr Reddys Laboratories Ltd listed on Dow Jones Sustainability Indices 2016 - Equity Bulls (NYSE:RDY) equitybulls.com - September 15 at 10:35 AM
	Dr. Reddy's Listed on Dow Jones Sustainability Indices 2016 - Yahoo Finance (NYSE:RDY) finance.yahoo.com - September 15 at 10:35 AM
	Dr Reddy Laboratories : listed on Dow Jones Sustainability Indices 2016 (NYSE:RDY) www.4-traders.com - September 14 at 7:08 PM
	Dr Reddys Laboratories Ltd listed on Dow Jones Sustainability Indices 2016 (NYSE:RDY) www.equitybulls.com - September 14 at 7:08 PM
	Analyst Expectations and Growth Review for Dr. Reddy's Laboratories Ltd. (NYSE:RDY) - Post News (NYSE:RDY) www.kentuckypostnews.com - September 14 at 11:22 AM
	Dr Reddy’s listed on Dow Jones Sustainability Indices 2016 (NYSE:RDY) www.publicnow.com - September 14 at 11:22 AM
	Can Shares Of Dr. Reddy's Laboratories Ltd (NYSE:RDY) Hit $56 - Investor Newswire (NYSE:RDY) www.investornewswire.com - September 13 at 11:52 AM
	Dr. Reddy's Listed on Dow Jones Sustainability Indices 2016 - Business Wire (press release) (NYSE:RDY) www.businesswire.com - September 13 at 11:52 AM
	Dr. Reddy’s Listed on Dow Jones Sustainability Indices 2016 (NYSE:RDY) au.finance.yahoo.com - September 13 at 11:52 AM
	Buy Dr. Reddy's Laboratories Ltd., target Rs 3300.0 : Reliance Securities (NYSE:RDY) economictimes.indiatimes.com - September 12 at 11:40 AM
	Analyst Projections and Growth Review for Dr. Reddy's Laboratories Ltd. (NYSE:RDY) - Post News (NYSE:RDY) www.kentuckypostnews.com - September 7 at 10:35 AM
	Dr. Reddy's announces Purple Health, a unique patient-centric platform that takes care beyond the pill (NYSE:RDY) www.equitybulls.com - September 6 at 11:46 AM
	Dr Reddy’s Laboratories to redesign packaging of its brands (NYSE:RDY) www.livemint.com - September 2 at 6:54 PM
	12:01 pm Dr. Reddy's launches Bupropion HCl extended-release tablets in the United States (NYSE:RDY) finance.yahoo.com - September 2 at 6:54 PM
	Dr. Reddy's Laboratories Announces the Launch of Bupropion HCl Extended-Release Tablets, USP (SR) in the US ... - Business Wire (press release) (NYSE:RDY) www.businesswire.com - September 2 at 11:56 AM
	Dr. Reddy's Laboratories Announces the Launch of Bupropion HCl Extended-Release Tablets, USP (SR) in the U.S. Market (NYSE:RDY) au.finance.yahoo.com - September 2 at 11:56 AM
	RDY Makes Bullish Cross Above Critical Moving Average (NYSE:RDY) www.nasdaq.com - September 1 at 10:09 AM
	Buy Dr. Reddy's Laboratories Ltd., target Rs 3300.0 : Tejas Shah (NYSE:RDY) economictimes.indiatimes.com - September 1 at 10:09 AM
	Dr. Reddys Announces Purple Health, a Unique Patient-Centric Platform That Takes Care beyond the Pill (NYSE:RDY) www.newson6.com - September 1 at 10:09 AM
	Dr. Reddy’s announces Purple Health, a unique patient-centric platform that takes care beyond the pill (NYSE:RDY) www.publicnow.com - September 1 at 10:09 AM
	RDY Makes Bullish Cross Above Critical Moving Average - Nasdaq (NYSE:RDY) www.nasdaq.com - August 30 at 6:56 PM
	Can Shares Of Dr. Reddy's Laboratories Ltd (NYSE:RDY) Get To $56? - Investor Newswire (NYSE:RDY) www.investornewswire.com - August 30 at 6:56 PM
	Form 6-K DR REDDYS LABORATORIES For: Aug 30 - StreetInsider.com (NYSE:RDY) www.streetinsider.com - August 30 at 6:56 PM
	Dr. Reddy's Laboratories Launches Nitroglycerin Sublingual Tablets USP in the U.S. Market Hyderabad, India, August ... - Yahoo Finance (NYSE:RDY) finance.yahoo.com - August 30 at 6:56 PM
	Buy Dr. Reddy's Laboratories Ltd., target Rs 3125.0 : Dr CK Narayan (NYSE:RDY) economictimes.indiatimes.com - August 30 at 10:19 AM
	Dr. Reddy's launches Nitroglycerin sublingual tablets in US (NYSE:RDY) health.economictimes.indiatimes.com - August 29 at 6:50 PM
	Dr. Reddy’s Laboratories launches heart drug in the US (NYSE:RDY) rtn.asia - August 29 at 6:50 PM
	Dr. Reddy's Laboratories Launches Nitroglycerin Sublingual Tablets USP in the U.S. ... (NYSE:RDY) www.biomedreports.com - August 29 at 6:50 PM
	Dr. Reddy's launches generic nitroglycerin tablets in U.S. (NYSE:RDY) seekingalpha.com - August 29 at 6:50 PM
	Dr. Reddy's Labs Launches Nitroglycerin Sublingual Tablets USP (NYSE:RDY) www.rttnews.com - August 29 at 6:50 PM
	Dr. Reddys Labs (RDY) Announces U.S. Launch of Generic Nitrostat Tabs (NYSE:RDY) www.streetinsider.com - August 29 at 6:50 PM
	Dr. Reddy's Laboratories Launches ... (NYSE:RDY) www.advfn.com - August 29 at 6:50 PM